US EditionPublished • loading... • Updated
Breakthrough Alzheimer’s drugs to be reconsidered for NHS
NICE will reassess two Alzheimer’s drugs after an appeal highlighted overlooked caregiver impacts and economic benefits, potentially helping 70,000 early-stage patients in England.
- The National Institute for Health and Care Excellence will re-evaluate its decision on pioneering Alzheimer drugs following successful appeals from manufacturers. This move offers thousands of patients hope of accessing the treatments on the NHS.
- Last year, Nice rejected the treatments for NHS use in England and Wales, concluding their benefits were "too small" to justify costs estimated at five to six times higher than its usual recommendation threshold.
- Manufacturers claimed the watchdog provided infusion cost documents only four days before the final committee meeting, limiting scrutiny. These drugs clear toxic protein from the brain, delaying cognitive decline by four to six months.
- Helen Knight, director of medicines evaluation at Nice, said the committee will allow stakeholders to provide information addressing areas of uncertainty. Chris Stokes of Lilly added, "This is a big moment in the battle against Alzheimer."
- With over 30 Alzheimer drugs in late-stage clinical trials, the NHS is urged to prepare for a new era of dementia treatment. More than 130 drugs are in development globally, underscoring the urgency for patients.
Insights by Ground AI
9 Articles
9 Articles
England to Review Rejection of Lilly Alzheimer’s Drug for NHS
England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly & Co.’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker.
·United States
Read Full Article
Coverage Details
Total News Sources9
Leaning Left3Leaning Right1Center3Last UpdatedBias Distribution43% Left, 43% Center
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
43% Center
L 43%
C 43%
14%
Factuality
To view factuality data please Upgrade to Premium
